Phase 4 N=18 HCV-HIV Co-infected Patient Cohort in Thailand
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
Phase 2 N=14 Lonafarnib for Chronic Hepatitis D
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
Phase 1 N=18 Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)
Hepatitis, Viral, Human
Primary: Mean Reduction From Baseline in Log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 5 - HCV GT1 — 4.25; 4.40; 3.56; 0.00 IU/mL
Phase 2 N=128 A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Hepatitis C
Primary: Comparison of Sustained Viral Response at 12 Weeks Post Treatment (SVR12) in the Three Treatment Groups. — 3; 5; 3; 30 Participants — p=0.67
Phase 4 N=32 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Hepatitis C, Chronic · Opioid-use Disorder
Primary: Number of Participants Initiating in Hepatitis C Virus (HCV) Treatment — 21 Participants
Phase 2 N=50 Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Hepatitis C · HIV
Primary: Percentage of Participants With Achieved SVR12 (HCV RNA <LLOQ 12 Weeks After Completion of Treatment) — 97; 100 percentage of participants
Phase 4 N=35 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Chronic Hepatitis C · Hemodialysis
Primary: 1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs) — 13; 8…
Phase 3 N=80 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
Acute Hepatitis C · Human Immunodeficiency Virus · Hepatitis C
Primary: SVR12 (Reinfection Not Considered Failure) — 79 participants
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
N/A N=182 Rapid HCV Treatment Access for Persons Who Use Drugs
Hepatitis C Virus Infection, Response to Therapy of
Primary: Participants Who Initiate HCV Therapy — 59; 12 Participants — p=<0.001
Phase 3 N=262 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
HIV Infections · Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) — 34.8; 25.4 percentage of participants
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants